Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)

Next Previous
Search
Trial Profile

Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ATLAS; ATTLAS

    • Most Recent Events

    • 01 Nov 2023 According to Lunit media release, the study will be presented at the upcoming SITC (Society for Immunotherapy of Cancer) 2023 Annual Meeting, taking place from November 1 to 5, in San Diego, California.
    • 24 Oct 2023 Results assessing the efficacy of atezolizumab plus bevacizumab and chemotherapy in EGFR or ALK-mutated NSCLC that progressed prior to TKI therapy presented at the 48th European Society for Medical Oncology Congress
    • 24 Oct 2023 Results presented in a Lunit media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top